2. Signaling Pathways
  3. PI3K/Akt/mTOR
  4. PI4K

PI4K

Phosphatidylinositol 4 kinases; PI4 kinases

PI4K

Related Products

PDF 0.23 MB

Phosphatidylinositol 4-kinases (PI4Ks) catalyze the synthesis of phosphatidylinositol 4-phosphate (PI4P), an important intermediate for the synthesis of membrane polyphosphoinositides, regulators of multiple cellular functions. PI4P defines the membranes of Golgi and trans-Golgi network (TGN) and regulates trafficking to and from the Golgi. Based on enzymatic differences, two classes of PI4K have been distinguished termed Types II (PI4KII) and III (PI4KIII), and each of which contains α and β isoforms.

PI4KII alpha and beta have similar biochemical properties. PI4KIIIs (α- and β-forms) are soluble enzymes structurally related to PI3-kinases, and sensitive to PI3-kinase inhibitors, such as Wortmannin. PI4KIIs produce PtdIns 4-phosphate, an early key signaling molecule in phosphatidylinositol cycle, which is indispensable for T cell activation. PI4KIIIs plays a key role in the production of replication complexes (viral factories) of a number of positive-sense RNA viruses and represents a potential target for novel pan-viral therapeutics.

PI4K Isoform Specific Products:

PI4K Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148956
    PI4KA-IN-1
    		Inhibitor
    PI4KA-IN-1 (Compound G1) is a PI4KA inhibitor. PI4KA-IN-1 can be used in the research of hepatitis C virus infection.
    PI4KA-IN-1
  • HY-103583R
    KDU731 (Standard)
    		Inhibitor
    KDU731 (Standard) is the analytical standard of KDU731 (HY-103583). This product is intended for research and analytical applications. KDU731, an orally active C. parvum PI4K inhibitor with an IC50 value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo. KDU731 is a promising agent candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety.
    KDU731 (Standard)
  • HY-178775
    PI4K-IN-3
    		Inhibitor
    PI4K-IN-3 (Compound 27) is an orally active PI4K inhibitor with an IC50 of 1.9  nM for Plasmodium vivax PI4K. PI4K-IN-3 has no hERG channel inhibition and mammalian cytotoxicity. PI4K-IN-3 has significant selectivity against the human MINK1 and MAP4K4 kinases but with low selectivity against human PI3Kα and PI4Kβ. PI4K-IN-3 has potent antimalarial activity and significantly reduces parasitaemia in NSG mice mouse models of Plasmodium falciparum malaria.
    PI4K-IN-3
  • HY-108313R
    T-00127_HEV1 (Standard)
    		Inhibitor
    T-00127_HEV1 (Standard) is the analytical standard of T-00127_HEV1 (HY-108313). This product is intended for research and analytical applications. T-00127_HEV1 is a phosphatidylinositol 4-Kinase III beta (PI4KB) inhibitor with an IC50 of 60 nM.
    T-00127_HEV1 (Standard)
  • HY-175557
    PI4K-IN-2
    		Inhibitor
    PI4K-IN-2 (Compound 30) is a highly selective type III phosphatidylinositol 4-kinase β (PI4KB) inhibitor (IC50=0.015 μM). PI4K-IN-2 is promising for research of human rhinovirus (HRV).
    PI4K-IN-2
  • HY-174130
    PI4Kβ/PKG-IN-1
    		Inhibitor
    PI4Kβ/PKG-IN-1 (Compound 19) is an orally active dual inhibitor targeting Plasmodium phosphatidylinositol 4-kinase beta (PI4Kβ) and cGMP-dependent protein kinase (PKG). PI4Kβ/PKG-IN-1 exhibits potent antiplasmodial activity. PI4Kβ/PKG-IN-1 is promising for research of malaria.
    PI4Kβ/PKG-IN-1
  • HY-106005R
    MMV390048 (Standard)
    		Inhibitor
    MMV390048 (Standard) is the analytical standard of MMV390048 (HY-106005). This product is intended for research and analytical applications. MMV390048 is a representative of a new chemical class of Plasmodium PI4K inhibitor (Kdapp=0.3 μM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns. MMV390048 is an antimalarial agent.
    MMV390048 (Standard)
  • HY-123536
    AZD2836
    		Inhibitor
    AZD2836 (A-831) is a 4-aminopyrazolone compound with anti-HCV activity. AZD2836 inhibits the activity of the host cell kinase PI4KIIIα, causing metabolic disorder of the cell membrane component PI4P that is necessary for viral replication. In the HCV subgenomic replicon cell model, the EC50 values of AZD2836 for genotype 1b (Con1 strain) and genotype 1a (Lemon strain) are 270 nM and 550 nM, respectively.
    AZD2836
  • HY-175732
    PI4Kβ-IN-1
    		Inhibitor
    PI4Kβ-IN-1 is an orally active and selective PI4Kβ inhibitor, with an IC50 of 0.9 nM. PI4Kβ-IN-1 exhibits inhibitory activity against all stages of the P. falciparum life cycle, including blood, liver, and transmission stages. PI4Kβ-IN-1 demonstrates potent antimalarial efficacy in the mouse model infected with Plasmodium falciparum. PI4Kβ-IN-1 can be used for the study of malaria caused by Plasmodium falciparum.
    PI4Kβ-IN-1
  • HY-103489R
    PI-273 (Standard)
    		Inhibitor
    PI-273 (Standard) is the analytical standard of PI-273 (HY-103489). This product is intended for research and analytical applications. PI-273 is a first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM. PI-273 can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.
    PI-273 (Standard)
  • HY-161357
    KR-27370
    		Inhibitor
    KR-27370 (compound 7f) is an antiviral agent and selective PI4KIIIβ/PI4KIIIα inhibitor (IC50: 3.1 nM/15.8 nM), against hRV, Ke Saatchivirus and other enteroviruses have inhibitory activity.
    KR-27370
  • HY-100603B
    (R)-GSK-F1
    		Inhibitor
    (R)-GSK-F1 is the R-type isomer of GSK-F1 (HY-100603). GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research.
    (R)-GSK-F1
PI4K Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.